AV7909 Full Dose (0.5 mL) + AV7909 Half Dose (0.25 mL) + Placebo: Sodium Chloride Injection, USP 0.9% (0.5 mL) + Placebo: Sodium Chloride Injection, USP 0.9% (0.25 mL)
Phase 2Active 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Anthrax
Conditions
Anthrax
Trial Timeline
Dec 5, 2023 → Aug 1, 2026
NCT ID
NCT05997264About AV7909 Full Dose (0.5 mL) + AV7909 Half Dose (0.25 mL) + Placebo: Sodium Chloride Injection, USP 0.9% (0.5 mL) + Placebo: Sodium Chloride Injection, USP 0.9% (0.25 mL)
AV7909 Full Dose (0.5 mL) + AV7909 Half Dose (0.25 mL) + Placebo: Sodium Chloride Injection, USP 0.9% (0.5 mL) + Placebo: Sodium Chloride Injection, USP 0.9% (0.25 mL) is a phase 2 stage product being developed by ICON plc. for Anthrax. The current trial status is active. This product is registered under clinical trial identifier NCT05997264. Target conditions include Anthrax.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05997264 | Phase 2 | Active |
Competing Products
15 competing products in Anthrax
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Cipro (Ciprofloxacin, BAYQ3939) | Bayer | Pre-clinical | 20 |
| AV7909 + BioThrax | Emergent BioSolutions | Phase 3 | 69 |
| AV7909 + BioThrax | Emergent BioSolutions | Phase 2 | 44 |
| AIGIV | Emergent BioSolutions | Pre-clinical | 15 |
| CYFENDUS | Emergent BioSolutions | Pre-clinical | 15 |
| BioThrax + Ciprofloxacin | Emergent BioSolutions | Phase 2 | 44 |
| BioThrax + AV7909 Formulation 1 + AV7909 Formulation 2 + AV7909 Formulation 3 + AV7909 Formulation 4 + Control | Emergent BioSolutions | Phase 1 | 25 |
| Ciprofloxacin 500Mg Tablet + Doxycycline 100Mg Tablet + AV7909 | Emergent BioSolutions | Phase 2 | 44 |
| AVP-21D9 + Placebo | Emergent BioSolutions | Phase 1 | 25 |
| AIGIV | Emergent BioSolutions | Pre-clinical | 15 |
| AIGIV 3.5 mg/kg + Gamunex 90 mg/kg + AIGIV 7.0 mg/kg + Gamunex 180 mg/kg + AIGIV 14.0 mg/kg + Gamunex 360 mg/kg | Emergent BioSolutions | Phase 1/2 | 33 |
| AVA + Ad4-PA-1 + Ad4-PA-GPI-1 | Emergent BioSolutions | Phase 1 | 25 |
| BioThrax | Emergent BioSolutions | Phase 3 | 69 |
| Raxibacumab | Emergent BioSolutions | Phase 2/3 | 57 |
| NP-015 | Emergent BioSolutions | Phase 1 | 25 |